These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17981565)

  • 21. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
    Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
    Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
    Niks EH; Aartsma-Rus A
    Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy.
    D'Ambrosio ES; Mendell JR
    Neurotherapeutics; 2023 Oct; 20(6):1669-1681. PubMed ID: 37673849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J; Zhang C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug; 28(4):406-8. PubMed ID: 21811980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
    van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
    Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.
    Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM
    J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene editing and modulation for Duchenne muscular dystrophy.
    Stephenson AA; Flanigan KM
    Prog Mol Biol Transl Sci; 2021; 182():225-255. PubMed ID: 34175043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular therapies for Duchenne muscular dystrophy].
    Takeshima Y
    No To Hattatsu; 2016 Jul; 48(4):241-6. PubMed ID: 30010301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.
    Aartsma-Rus A; Straub V; Hemmings R; Haas M; Schlosser-Weber G; Stoyanova-Beninska V; Mercuri E; Muntoni F; Sepodes B; Vroom E; Balabanov P
    Nucleic Acid Ther; 2017 Oct; 27(5):251-259. PubMed ID: 28796573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview on DMD exon skipping.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.
    Robinson-Hamm JN; Gersbach CA
    Hum Genet; 2016 Sep; 135(9):1029-40. PubMed ID: 27542949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
    Takeshima Y
    Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.